Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices surge to two-week winning streak as Iran supply fears grip markets Wall Street posts three-week losing streak as Iran war batters sentiment Iran latest: Hegseth promises that U.S. military will reopen Strait of Hormuz Gold set for a two-week losing run as spiking oil prices spur inflation concerns 🧠 Upgrade to AI Insights (South Africa Philippines Nigeria) 🧠 Upgrade to AI Insights Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million By Insider Trading Published 03/13/2026, 08:49 PM Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million 0 DNTH -3.06% Simrat Randhawa, Executive Vice President, Head of R&D, at Dianthus Therapeutics, Inc. (NASDAQ:DNTH) , sold 33,830 shares of common stock on March 12, 2026, for a total of $2,756,468. The shares were sold at a price of $81.48. On the same day, Randhawa also exercised options to acquire a total of 33,830 shares of Dianthus Therapeutics common stock, in a series of transactions. These shares were acquired at prices ranging from $8.44 to $22.07, for a total value of $614,165. An InvestingPro tip notes the company holds more cash than debt on its balance sheet, with 16 additional exclusive tips available to subscribers. In other recent news, Dianthus Therapeutics completed a significant underwritten public offering, raising approximately $719 million in gross proceeds. The company sold 8,470,989 shares of common stock at $81 per share, including shares from the full exercise of the underwriters’ option to purchase additional shares. Additionally, Dianthus issued pre-funded warrants to purchase up to 402,468 shares at $80.999 per warrant, which are exercisable immediately. Previously, the company had announced a $625 million stock offering at the same price per share. Raymond James upgraded Dianthus Therapeutics to a Strong Buy, raising its price target to $123 due to positive interim results from the Phase 3 CAPTIVATE study in chro...
Read full article at source